Agile Therapeutics, Inc.

Equities

AGRX

US00847L3087

Biotechnology & Medical Research

Market Closed - OTC Markets 03:44:52 2024-04-19 pm EDT 5-day change 1st Jan Change
0.38 USD +2.70% Intraday chart for Agile Therapeutics, Inc. +4.37% -80.51%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024
Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q4 Revenue $3.6M MT
Agile Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Agile Therapeutics, Inc.(OTCPK:AGRX) dropped from S&P TMI Index CI
Agile Therapeutics, Inc.(OTCPK:AGRX) dropped from NASDAQ Composite Index CI
North American Morning Briefing : Stocks Struggle After New Records DJ
North American Morning Briefing : Stock Futures -2- DJ
Maxim Downgrades Agile Therapeutics to Hold From Buy MT
Agile Therapeutics Inc. Completes Pay-Off the Remainder of its Debt Facility CI
Top Premarket Gainers MT
Agile Therapeutics, Inc. Announces Senior Secured Term Loan Credit Facility of Up to $35.0 Million CI
Agile Therapeutics, Inc. Provides Revenue Guidance for the Full Year Ended December 31, 2023 CI
Agile Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Agile Therapeutics, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Agile Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023 CI
Earnings Flash (AGRX) AGILE THERAPEUTICS Reports Q3 Revenue $6.7M, vs. Street Est of $6.35M MT
North American Morning Briefing : Traders Await -2- DJ
North American Morning Briefing : Stock Futures -2- DJ
Maxim Upgrades Agile Therapeutics to Buy From Hold With $5 Price Target MT
Agile Therapeutics, Inc. Affirms Revenue Guidance for the Year 2023 CI
Transcript : Agile Therapeutics, Inc., Q2 2023 Earnings Call, Aug 09, 2023
Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q2 Revenue $5.5M MT
Agile Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Agile Therapeutics, Inc. Provides Revenue Guidance for the Year 2023 CI
Agile Therapeutics, Inc. Announces Executive Changes CI
Chart Agile Therapeutics, Inc.
More charts
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.
More about the company
  1. Stock Market
  2. Equities
  3. AGRX Stock
  4. News Agile Therapeutics, Inc.
  5. Agile Therapeutics : HC Wainwright Adjusts Agile Therapeutics PT to $3.50 From $7, Maintains Buy Rating